Breaking Down Twist Bioscience: 5 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Twist Bioscience (NASDAQ:TWST) has been evaluated by 5 analysts in the past three months, showing a shift towards a somewhat bullish stance with all 5 recent ratings being somewhat bullish. The average 12-month price target for TWST has been raised to $44.6, indicating a 4.69% increase from the previous target of $42.60. Analysts from firms including Scotiabank, Evercore ISI Group, Barclays, and Baird have adjusted their price targets and ratings, reflecting optimism about the company's market position and financial health despite its revenue growth trailing behind the industry average and a negative net margin.
May 06, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience has received updated somewhat bullish ratings from 5 analysts, with a raised average 12-month price target of $44.6. This reflects a positive outlook on the company's financial health and market position.
The unanimous somewhat bullish stance from analysts, coupled with the raised price targets, suggests a positive short-term outlook for TWST. The adjustments in ratings and targets reflect analysts' optimism about the company's future performance, potentially influencing investor sentiment and stock price positively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100